AR040600A1 - Composicion farmaceutica estable que comprende eritropoietina - Google Patents
Composicion farmaceutica estable que comprende eritropoietinaInfo
- Publication number
- AR040600A1 AR040600A1 AR20030102576A ARP030102576A AR040600A1 AR 040600 A1 AR040600 A1 AR 040600A1 AR 20030102576 A AR20030102576 A AR 20030102576A AR P030102576 A ARP030102576 A AR P030102576A AR 040600 A1 AR040600 A1 AR 040600A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- stable pharmaceutical
- erythropoietin
- epo
- pvp
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 5
- 108090000394 Erythropoietin Proteins 0.000 title abstract 5
- 229940105423 erythropoietin Drugs 0.000 title abstract 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000654 additive Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente provee una nueva composición farmacéutica estable de eritropoietina (EPO) que se estabiliza con PVP como estabilizador único. Reivindicación 1: Una composición farmacéutica estable de eritropoietina, que comprende: a) una cantidad terapéuticamente eficaz de EPO, b) un sistema regulador de pH farmacéuticamente aceptable, c) PVP y en forma opcional, además comprende: d) un agente isotonificante, e) uno o más excipientes farmacéuticamente aceptables, y está libre de aditivos de origen humano y/o animal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200200176A SI21257A (sl) | 2002-07-17 | 2002-07-17 | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040600A1 true AR040600A1 (es) | 2005-04-13 |
Family
ID=30113491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102576A AR040600A1 (es) | 2002-07-17 | 2003-07-17 | Composicion farmaceutica estable que comprende eritropoietina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8648175B2 (es) |
| EP (1) | EP1536822B1 (es) |
| JP (1) | JP4979191B2 (es) |
| CN (1) | CN100425283C (es) |
| AR (1) | AR040600A1 (es) |
| AT (1) | ATE330623T1 (es) |
| AU (1) | AU2002368075B2 (es) |
| CA (1) | CA2492470C (es) |
| DE (1) | DE60212728T2 (es) |
| ES (1) | ES2268166T3 (es) |
| MX (1) | MXPA05000661A (es) |
| SI (1) | SI21257A (es) |
| WO (1) | WO2004006948A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101005853B (zh) | 2004-07-26 | 2011-05-04 | 莫茨药物股份两合公司 | 包含肉毒杆菌神经毒素的治疗组合物 |
| WO2007108505A1 (ja) * | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
| AU2014279627A1 (en) * | 2013-06-09 | 2015-12-03 | Efranat Ltd. | Compositions comprising Gc- macrophage activating factor and uses thereof |
| WO2019157453A1 (en) | 2018-02-12 | 2019-08-15 | Trilogy Therapeutics, Inc. | Caspofungin compositions for inhalation |
| CN118338910A (zh) * | 2021-12-03 | 2024-07-12 | 杰科（天津）生物医药有限公司 | 一种制剂及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
| JPS63146828A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| DE4126984A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke |
| JPH0952844A (ja) * | 1995-08-10 | 1997-02-25 | Amano Pharmaceut Co Ltd | 酵素含有内服液剤 |
| TW518219B (en) * | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
-
2002
- 2002-07-17 SI SI200200176A patent/SI21257A/sl not_active IP Right Cessation
- 2002-11-08 WO PCT/IB2002/004690 patent/WO2004006948A1/en not_active Ceased
- 2002-11-08 AT AT02807598T patent/ATE330623T1/de not_active IP Right Cessation
- 2002-11-08 CA CA2492470A patent/CA2492470C/en not_active Expired - Lifetime
- 2002-11-08 CN CNB028293290A patent/CN100425283C/zh not_active Expired - Fee Related
- 2002-11-08 US US10/521,296 patent/US8648175B2/en not_active Expired - Fee Related
- 2002-11-08 AU AU2002368075A patent/AU2002368075B2/en not_active Ceased
- 2002-11-08 MX MXPA05000661A patent/MXPA05000661A/es active IP Right Grant
- 2002-11-08 ES ES02807598T patent/ES2268166T3/es not_active Expired - Lifetime
- 2002-11-08 DE DE60212728T patent/DE60212728T2/de not_active Expired - Lifetime
- 2002-11-08 EP EP02807598A patent/EP1536822B1/en not_active Expired - Lifetime
- 2002-11-08 JP JP2004520930A patent/JP4979191B2/ja not_active Expired - Fee Related
-
2003
- 2003-07-17 AR AR20030102576A patent/AR040600A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SI21257A (sl) | 2004-02-29 |
| AU2002368075A1 (en) | 2004-02-02 |
| ATE330623T1 (de) | 2006-07-15 |
| AU2002368075B2 (en) | 2007-07-05 |
| CA2492470A1 (en) | 2004-01-22 |
| CA2492470C (en) | 2012-08-28 |
| US8648175B2 (en) | 2014-02-11 |
| JP4979191B2 (ja) | 2012-07-18 |
| CN100425283C (zh) | 2008-10-15 |
| EP1536822A1 (en) | 2005-06-08 |
| US20050238720A1 (en) | 2005-10-27 |
| JP2006501193A (ja) | 2006-01-12 |
| WO2004006948A1 (en) | 2004-01-22 |
| EP1536822B1 (en) | 2006-06-21 |
| MXPA05000661A (es) | 2005-08-19 |
| ES2268166T3 (es) | 2007-03-16 |
| CN1638791A (zh) | 2005-07-13 |
| DE60212728T2 (de) | 2007-06-28 |
| DE60212728D1 (de) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02011303A (es) | Nueva composicion farmaceutica. | |
| PA8575701A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| AR027391A1 (es) | Composiciones farmaceuticas de toxina botulinica | |
| PT991407E (pt) | Estabilizacao de benzimidazoles sensiveis a acidos com combinacoes de amino/ciclodextrinas | |
| EP1226104A4 (en) | PHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS USED TO DIFFUSER ACTIVE AGENTS | |
| BR0109943A (pt) | Composições farmacêuticas | |
| BR0108816A (pt) | Derivados de quinolina como antagonistas alfa-2 | |
| PT994710E (pt) | Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina | |
| MXPA05001061A (es) | Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol. | |
| CU23367A3 (es) | Formulación de moxifloxacino con sal común | |
| AR034343A1 (es) | Combinaciones farmaceuticas | |
| BRPI0017528B8 (pt) | uso de uma composição contendo sal de cetotifeno | |
| IS6654A (is) | Stöðugt gabapentín með pH innan stýrðra marka | |
| AR040600A1 (es) | Composicion farmaceutica estable que comprende eritropoietina | |
| BR0311479A (pt) | Derivados de tiofeno antelmìnticos e inseticidas | |
| PT1200088E (pt) | Composicao contendo paracetamol e drotaverina | |
| BR0010699A (pt) | Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários | |
| NO20031650D0 (no) | Nye legemidler for leversykdommer | |
| HN2000000090A (es) | Sal difosfato de un derivado de 4sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica. | |
| DK1178960T3 (da) | Vitamin D analoger og deres farmaceutiske anvendelse | |
| ES2149736T1 (es) | Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes. | |
| ATE301469T1 (de) | Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase | |
| BR0313076A (pt) | Sal de ácido orgânico de amlodipina | |
| DE60121142D1 (de) | Zusammensetzung die paracetamol und niflumic säure enthält | |
| BRPI0516957A (pt) | formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |